SCHEMBL5584528

SCHEMBL5584528

COc1cccc2oc(C#N)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
CNR2 P34972 1/20 0.47
MAOA P21397 2/20 0.44
CNR1 P21554 1/20 0.44
GPR55 Q9Y2T6 1/20 0.44
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.43
F2RL3 Q96RI0 3/20 0.42
IMPDH2 P12268 1/20 0.41
IMPDH1 P20839 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ACHE P22303 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632984 0.90 CYP2A6 (0.45) CYP2A6CA12CA1CA2CA9
SCHEMBL16632454 0.84 AR (0.41) CYP2A6CA12CA1CA2CA9
SCHEMBL16632723 0.83 SLC6A4 (0.49) CA1CA2MAOANPC1ALDH1A1
SCHEMBL6961672 0.80 ALDH1A1 (0.58) CYP2A6MAOANPC1ALDH1A1KDM4E
SCHEMBL16632479 0.77 CYP2A6 (0.45) CYP2A6CA12CA1CA2CA9
SCHEMBL16632752 0.77 CNR2 (0.45) CYP2A6CNR2GPR55ALDH1A1KDM4E
SCHEMBL806615 0.77 CNR2 (0.45) CYP2A6CNR2GPR55ALDH1A1KDM4E
SCHEMBL16632531 0.76 SLC6A4 (0.42) CYP2A6CA1CA2NPC1ALDH1A1
SCHEMBL9296788 0.75 CYP2A6 (0.56) CYP2A6CA12CA1CA2CA9
SCHEMBL24276015 0.74 CYP2A6 (0.54) CYP2A6CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A CYP2A6 956/4885CA12 4877/4885CA1 3979/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A CYP2A6 956/4885CA12 4877/4885CA1 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.